Abionyx Pharma

LTS:0RAG (France)   Ordinary Shares
€ 1.23 (0%) Jul 1
At Loss
P/B:
4.73
Market Cap:
€ 37.61M ($ 40.42M)
Enterprise V:
€ 36.90M ($ 39.65M)
Volume:
-
Avg Vol (2M):
92.00
Trade In:

Business Description

Description
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
Name Current Vs Industry Vs History
Cash-To-Debt 1.21
Equity-to-Asset 0.53
Debt-to-Equity 0.43
Debt-to-EBITDA -1.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.7
Distress
Grey
Safe
Beneish M-Score -2.72
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 20.62
9-Day RSI 35.76
14-Day RSI 46.17
6-1 Month Momentum % -0.47
12-1 Month Momentum % 1.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.75
Quick Ratio 1.7
Cash Ratio 1.05
Days Inventory 15.94
Days Sales Outstanding 67.55
Days Payable 157.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.7
Shareholder Yield % -10.03